# Federal Research Peptide Policy in 2026

Canonical source: https://retacompare.com/research/federal-research-peptide-policy-2026-169

Schedule II & RFK · 2026-03-23


    Federal research peptide policy spans multiple agencies: FDA regulates therapeutic products, NIH funds research, DEA handles scheduling where applicable, and HHS coordinates overall policy. The 2026 HHS peptide policy review has formally inventoried the federal research peptide landscape and identified points of friction: NIH IND requirements for early-phase peptide studies, FDA approach to peptide-specific INDs, and the distinction between research use only and therapeutic intent. RFK Jr.'s stated priorities include expanding early-phase peptide research funding and clarifying regulatory pathways. Implementation of these priorities is proceeding through both budget processes and guidance development.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources